Fluphenazine Enanthate
drugOn this page
Also known as FlufenanFluphenazine enantateFluphenazini enantasModiten enantProlixin enanthateSQ 16,114SQ 16144SA-16144
Summary
Fluphenazine Enanthate (CHEMBL1200951) is an approved small molecule; indicated across 5 conditions including anxiety and dementia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 5 conditions
- Chemistry: 549.7 Da · C29H38F3N3O2S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200951 |
| Name | Fluphenazine Enanthate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 3389 |
| Molecular formula | C29H38F3N3O2S |
| Molecular weight | 549.7 |
| InChIKey | LRWSFOSWNAQHHW-UHFFFAOYSA-N |
SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
IUPAC name: 2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate
Also known as: Flufenan, Fluphenazine enantate, Fluphenazine enanthate, Fluphenazini enantas, Moditen enant, Prolixin enanthate, SQ 16,114, SQ 16144, FLUPHENAZINE ENANTHATE, SA-16144
Patent coverage: 507 distinct patent families (1,718 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,698 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anxiety | 3 | MONDO:0011918 | EFO:0005230 |
| dementia | 3 | MONDO:0001627 | HP:0000726 |
| depressive disorder | 3 | MONDO:0002050 | MONDO:0002050 |
| psoriasis | 2 | MONDO:0005083 | EFO:0000676 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anxiety, dementia, depressive disorder